Video

Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates

Author(s):

Nikhil Kushalani, MD,Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

Related Videos
Peter Forsyth, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Richard Kim, MD, Moffitt Cancer Center
Tiago Biachi, MD, PhD
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors

Blessy Mathew Jacob, MD; Ana Van Der Wall, MD; Vance M. Wright-Browne, MD
February 8th 2024

Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

Radiomic Biomarkers in Uveal Melanoma Metastases | Image Credit: © ReisMedia - stock.adobe.com
November 7th 2024

Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27